Skip to main content
    I

    Inhibikase Therapeutics Inc (IKT)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.45
    -0.07 (-4.61%)

    Market Cap: $213.21M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Inhibikase Therapeutics Inc (IKT) Financials: Revenue, Profit and Cash Flow

    Updated Nov 10, 2026. Financial statements from company filings, amounts in US dollars.

    Inhibikase Therapeutics reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$48.26M, operating cash flow was -$27.79M and free cash flow was -$27.80M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$20.47M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $51.97M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$0N/AN/AN/AN/A
    Dec 2024$0N/AN/AN/AN/A
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0N/AN/AN/AN/A
    Dec 2020$0-100.0%N/AN/AN/A
    Dec 2019$1.12M-72.2%-127.4%-507.5%-511.9%
    Dec 2018$4.04M+96.1%100.0%-52.5%-53.3%
    Dec 2017$2.06M+113.0%14.8%-19.7%-21.2%
    Dec 2016$967.39KN/A12.5%-63.4%-65.0%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$0$0$0$0$0$0$1.12M$4.04M$2.06M$967.39K
    Cost of revenue$0$0$0$0$0$0$2.55M$3.65M$1.76M$846.39K
    Gross profit$0$0$0$0$0$0-$1.43M$4.04M$305.25K$121.00K
    Research and development$29.79M$17.21M$13.62M$12.03M$11.36M$893.80K$2.55M$3.65M$1.76M$846.39K
    Operating income-$51.97M-$28.59M-$20.09M-$18.13M-$14.77M-$2.82M-$5.70M-$2.12M-$405.13K-$613.29K
    Net income-$48.26M-$27.52M-$19.03M-$18.05M-$14.79M-$2.85M-$5.75M-$2.15M-$436.07K-$628.74K
    EBITDA-$51.91MN/A-$19.91M-$18.12M-$14.77M-$2.82M-$5.70M-$2.12MN/AN/A
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$0$0$0$0$0$0$0$26.27K$0$0$0-$195.98K
    Gross profit$0$0$0-$36.81K$0$0$0-$6.57K$0$0$0-$195.98K
    Operating income-$22.23M-$21.05M-$17.84M-$13.78M-$12.77M-$10.83M-$14.60M-$12.93M-$5.83M-$5.05M-$4.78M-$4.40M
    Net income-$20.47M-$19.59M-$16.38M-$12.73M-$11.93M-$9.92M-$13.68M-$12.13M-$5.78M-$4.96M-$4.65M-$4.18M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $0 by $139.22M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$181.20M$98.60M$14.51M$24.94M$42.47M$14.78M$38.25K$2.85M$285.17K$162.93K
    Current assets$180.11M$98.45M$14.21M$24.37M$42.47M$14.78M$35.38K$1.25M$198.07K$80.16K
    Cash and equivalents$139.22M$56.49M$9.17M$7.19M$40.75M$13.95M$18.46K$379.56K$16.66K$12.04K
    Total liabilities$8.30M$3.73M$3.53M$3.90M$4.05M$5.00M$4.53M$3.62M$1.73M$1.51M
    Short-term debt$0$110.52K$150.09K$145.84K$0$42.53K$98.42K$233.73K$459.96K$328.94K
    Long-term debtN/AN/AN/AN/AN/A$276.46K$275.38KN/AN/AN/A
    Shareholder equity$172.90M$94.87M$10.98M$21.04M$38.42M$9.78M-$4.49M-$777.97K-$1.44M-$1.35M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$201.75M$163.59M$173.33M$181.20M$79.59M$88.85M$94.28M$98.60M$4.38M$8.83M$11.07M$14.51M
    Total liabilities$12.96M$10.26M$5.71M$8.30M$6.70M$8.80M$8.55M$3.73M$4.91M$3.73M$4.29M$3.53M
    Cash and equivalents$51.70M$31.21M$49.57M$139.22M$38.27M$77.74M$73.44M$56.49M$913.42K$3.09M$2.35M$9.17M
    Shareholder equity$188.80M$153.33M$167.62M$172.90M$72.90M$80.05M$85.73M$94.87M-$530.59K$5.10M$6.78M$10.98M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$27.79M-$19.15M-$18.09M-$17.35M-$14.30M-$1.13M-$338.29K$714.99K-$126.39K-$29.57K
    Capital expenditures$13.40K$0$14.24K$243.25K$0$0$0$0$0$0
    Free cash flow-$27.80M-$19.15M-$18.10M-$17.59M-$14.30M-$1.13M-$338.29K$714.99K-$126.39K-$29.57K
    Dividends paidN/AN/AN/AN/A$77.65KN/AN/AN/AN/AN/A
    Investing cash flow$2.05M-$37.00M$11.66M-$16.01M$0$0N/A$87.10K$87.10K$87.10K
    Financing cash flow$108.46M$103.48M$8.41M-$204.77K$41.09M$15.06M-$22.81K-$439.19K$131.02K-$23.77K
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$17.35M-$12.44M-$12.06M-$7.52M-$10.59M-$5.57M-$4.10M-$5.35M-$4.88M-$5.05M-$3.87M-$3.44M
    Capital expendituresN/AN/A$0$452.02K$452.02K$0$13.40K$0$4$4$0$14.24K
    Free cash flowN/AN/A-$12.06M-$7.97M-$11.04M-$5.57M-$4.12M-$5.35M-$4.88M-$5.05M-$3.87M-$3.46M
    Last 12 quarters

    Frequently Asked Questions About IKT

    What is Inhibikase Therapeutics' annual revenue?

    Inhibikase Therapeutics reported revenue of $0 for the fiscal year ended Dec 31, 2025.

    Is Inhibikase Therapeutics profitable?

    No. Inhibikase Therapeutics reported net income of -$48.26M for the fiscal year ended Dec 31, 2025.

    How much free cash flow does IKT generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$27.79M minus capital expenditures of $13.40K produced free cash flow of -$27.80M.

    How much debt does Inhibikase Therapeutics have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $0 and cash and equivalents of $139.22M.